Research ArticleIMMUNOTHERAPY

Platelets subvert T cell immunity against cancer via GARP-TGFβ axis

See allHide authors and affiliations

Science Immunology  05 May 2017:
Vol. 2, Issue 11, eaai7911
DOI: 10.1126/sciimmunol.aai7911

You are currently viewing the editor's summary.

View Full Text

Cancer immunotherapy according to GARP

Cancer, like microbes, can adapt to a single therapy, making combination therapies the approach of choice. Complementary therapies that decrease immunosuppression may boost the efficacy of immunotherapies. Now, Rachidi et al. report that targeting platelets improves adoptive T cell therapy of multiple cancers in mice. They found that transforming growth factor β (TGFβ) from platelets decrease T cell function largely through the expression of the TGFβ-docking receptor glycoprotein A repetitions predominant (GARP). These data suggest that combining immunotherapy with platelet inhibitors may be a complementary approach to cancer therapy.